Simcere Pharmaceutical Group Announces Resignation of an Independent Director

Simcere Pharmaceutical Group Announces Resignation of an Independent Director

10/12/2012 9:52:36 AM

NANJING, China, Oct. 12, 2012 -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China, today announced the resignation of Mr. Gary Siu Kwan Sik, an independent director of the Company, effective from October 11, 2012. Mr. Sik resigned for health and personal reasons. Mr. Sik has confirmed that he has no disagreement with the Company or any other board members. The Company appreciates the service that Mr. Sik has provided to the Company. Simcere is actively recruiting a replacement for Mr. Sik.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:

Email: [email protected]

In Nanjing:

Jie Liu D'Elia

Vice President

Simcere Pharmaceutical Group

Tel: 1-425-985-5530

In the United States:

Patricia Graue

Brunswick Group LLC

Tel: 1-415-671-7676

In Beijing:

Yue Yu

Brunswick Group

Tel: 86-10-5960-8600

 

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000

SOURCE Simcere Pharmaceutical Group

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.